Antiviral Activity of Benzavir-2 against Emerging Flaviviruses.
Zika virus
antiviral drugs
benzavir-2
flavivirus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
22 03 2020
22 03 2020
Historique:
received:
24
02
2020
revised:
16
03
2020
accepted:
18
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
18
2
2021
Statut:
epublish
Résumé
Most flaviviruses are arthropod-borne viruses, transmitted by either ticks or mosquitoes, and cause morbidity and mortality worldwide. They are endemic in many countries and have recently emerged in new regions, such as the Zika virus (ZIKV) in South-and Central America, the West Nile virus (WNV) in North America, and the Yellow fever virus (YFV) in Brazil and many African countries, highlighting the need for preparedness. Currently, there are no antiviral drugs available to treat flavivirus infections. We have previously discovered a broad-spectrum antiviral compound, benzavir-2, with potent antiviral activity against both DNA- and RNA-viruses. Our purpose was to investigate the inhibitory activity of benzavir-2 against flaviviruses. We used a ZIKV ZsGreen-expressing vector, two lineages of wild-type ZIKV, and other medically important flaviviruses. Benzavir-2 inhibited ZIKV derived reporter gene expression with an EC
Identifiants
pubmed: 32235763
pii: v12030351
doi: 10.3390/v12030351
pmc: PMC7150796
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
mBio. 2015 Dec 15;6(6):e01960-15
pubmed: 26670386
Sci Rep. 2017 Jul 7;7(1):4848
pubmed: 28687779
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Nat Rev Microbiol. 2005 Jan;3(1):13-22
pubmed: 15608696
J Enzyme Inhib Med Chem. 2008 Dec;23(6):931-45
pubmed: 18608772
PLoS One. 2015 Sep 28;10(9):e0138760
pubmed: 26413745
Arch Virol. 2017 Sep;162(9):2847-2853
pubmed: 28597088
PLoS One. 2017 Sep 21;12(9):e0185263
pubmed: 28934352
Antivir Ther. 2017;22(7):613-618
pubmed: 28694390
PLoS Pathog. 2016 Aug 22;12(8):e1005800
pubmed: 27548280
Cell Host Microbe. 2009 Apr 23;5(4):318-28
pubmed: 19380111
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30181371
Viruses. 2011 Feb;3(2):160-71
pubmed: 22049308
Viruses. 2017 Jan 19;9(1):
pubmed: 28106839
Front Cell Infect Microbiol. 2018 Nov 12;8:398
pubmed: 30483483
J Med Chem. 2012 Apr 12;55(7):3170-81
pubmed: 22369233
J Neuroinflammation. 2018 Mar 15;15(1):80
pubmed: 29544502
J Vis Exp. 2014 Nov 04;(93):e52065
pubmed: 25407402
Viruses. 2018 Feb 09;10(2):
pubmed: 29425176
Sci Rep. 2018 Jan 31;8(1):1925
pubmed: 29386590
J Infect Dis. 2000 Oct;182(4):1214-7
pubmed: 10979920
Viruses. 2017 Apr 30;9(5):
pubmed: 28468299
Antimicrob Agents Chemother. 2009 Jan;53(1):202-9
pubmed: 18955536
Front Immunol. 2018 Jul 18;9:1640
pubmed: 30072993
Emerg Microbes Infect. 2018 Sep 26;7(1):159
pubmed: 30254274
J Vis Exp. 2016 Aug 23;(114):
pubmed: 27584546
Emerg Infect Dis. 2015 Jan;21(1):181-2
pubmed: 25531820
Curr Opin Pharmacol. 2016 Oct;30:1-7
pubmed: 27367615
J Virol. 2018 Mar 14;92(7):
pubmed: 29321318
Methods Mol Biol. 2011;740:27-32
pubmed: 21468965
Cell Host Microbe. 2016 Aug 10;20(2):259-70
pubmed: 27476412
J Virol. 2010 Sep;84(17):8470-83
pubmed: 20554782
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061280
Lancet. 2007 Apr 28;369(9571):1452-1459
pubmed: 17467515
Acta Virol. 1994 Jun;38(3):141-9
pubmed: 7817895
Cell Rep. 2017 Dec 12;21(11):3032-3039
pubmed: 29241533
Lancet. 2008 Feb 9;371(9611):500-9
pubmed: 18262042
Cell Host Microbe. 2016 Jun 8;19(6):891-900
pubmed: 27198478
J Gen Virol. 2017 Nov;98(11):2712-2724
pubmed: 29022864
Antimicrob Agents Chemother. 2010 Sep;54(9):3871-7
pubmed: 20585112
N Engl J Med. 2016 May 19;374(20):1981-7
pubmed: 27074377
Antimicrob Agents Chemother. 2012 Nov;56(11):5735-43
pubmed: 22908173
PLoS Negl Trop Dis. 2017 Mar 9;11(3):e0005366
pubmed: 28278157
Antiviral Res. 2017 Feb;138:47-56
pubmed: 27919709
Prog Med Virol. 1975;19:257-323
pubmed: 164052